Delivery Order SPE2DR25D1205-SPE2DR26F0YR9
- Not listed
- The Defense Logistics Agency awarded a $17,675.30 firm fixed price delivery order to AmerisourceBergen Drug Corp for Mounjaro 10 mg/0.5 mL pen injections on November 24, 2025, with completion scheduled for November 25, 2025. This competitively awarded, non-set-aside contract represents a single delivery order fulfilling federal pharmaceutical procurement needs. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's...
- The Defense Logistics Agency awarded a $19,201.24 delivery order to AmerisourceBergen Drug Corp on November 20, 2025, for the supply of Mounjaro 10 mg/0.5 ml pen injections (0.5 ml). This competitive award utilizes firm fixed pricing and is scheduled for completion by November 21, 2025. The contract is a non-set-aside delivery order, indicating it was awarded through open competition. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,576.01 on December 10, 2025, for the supply of Mounjaro 5 mg/0.5 ml pen injections (0.5 ml). This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of December 11, 2025. The product will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order represents a child...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $31,479.14 to AmerisourceBergen Drug Corp for the supply of Mounjaro 12.5 mg/0.5 mL pen injections. The contract, awarded on November 18, 2025, with an ultimate completion date of November 19, 2025, carries firm fixed pricing and represents a non-competitive set-aside delivery order. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform all work at its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $2,720.17 to AmerisourceBergen Drug Corp on November 5, 2025, for the supply of Mounjaro 5 mg/0.5 mL pen injectors. This competitive award, with no set-aside designation, represents a firm fixed-price delivery order with an ultimate completion date of November 6, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate office. This delivery order...
- The Defense Logistics Agency awarded a $3,951.30 delivery order to AmerisourceBergen Drug Corp on December 11, 2025, for the supply of Mounjaro 5 mg/0.5 mL pen injections. This is a firm fixed-price delivery order with an ultimate completion date of December 12, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $5,713.89 delivery order to AmerisourceBergen Drug Corp for Mounjaro 10 mg/0.5 ml pen injections on June 2, 2025, with an ultimate completion date of June 3, 2025. This is a firm fixed price, non-set-aside contract with performance in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. AmerisourceBergen Drug Corp, a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a $1,317.10 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 15 mg/0.5 mL pen injections on November 12, 2025, with an ultimate completion date of November 13, 2025. The award, issued without set-aside provisions, will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $2,038.82 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 mL pen injectors. This competitive award, issued on November 3, 2025, with an ultimate completion date of November 4, 2025, represents a firm fixed-price transaction with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery order at its corporate...
- The Defense Logistics Agency awarded a $4,683.69 delivery order to AmerisourceBergen Drug Corp on November 20, 2025, for the supply of Mounjaro 7.5 mg/0.5 ml pen injectors. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by November 21, 2025, and will be fulfilled from the contractor's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DR25D1205Indefinite Delivery Contract
- SPE2DR25D1205-SPE2DR26F0YR9Delivery Order
The Defense Logistics Agency awarded a $17,864.31 firm fixed price delivery order to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 mL pen injections, with an ultimate completion date of December 22, 2025. This non-set-aside competitive award represents a single delivery order fulfillment under the company's broader pharmaceutical supply contract with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with the place of performance identified at its corporate office location in Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems globally. The delivery order for Mounjaro, a diabetes medication, exemplifies the company's role in providing brand-name pharmaceuticals across multiple therapeutic domains to the Defense Health Agency and other federal healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.9k | 12/18/25 |